Tempus, Pfizer Partner to Advance Oncology Therapeutic Development

Tempus, an artificial intelligence (AI) and precision medicine company, has announced a multi-year, strategic collaboration with Pfizer. Both the companies will be working together to further AI and machine learning-driven efforts in therapeutic development. 

The goal of this collaboration is to more precisely gather insights that will inform novel drug discovery and development in oncology.

Through this collaboration, Pfizer has access to Tempus’ AI-enabled platform and its library of de-identified, multimodal data to uncover insights that will power therapeutic development in oncology. Pfizer also has access to Tempus’ broad range of capabilities that support therapeutic R&D, to advance its own oncology portfolio, including AI-driven companion diagnostic offerings and Tempus’ clinical trial matching program, TIME, that rapidly activates studies for patients in communities across the country.

“Pfizer shares our commitment to bringing novel treatments to patients faster, and we look forward to working together to usher in the next generation of oncology therapeutics,” said Eric Lefkofsky, Founder and CEO of Tempus. “This is the third strategic collaboration Tempus has established with a global pharmaceutical leader in the last year, as we believe that combining our technological capabilities with pharma’s deep R&D expertise will get us much closer in realizing the full potential of precision medicine.”

This agreement comes less than a week after Tempus announced a partnership with Actuate Therapeutics to discover biomarkers of response to a cancer drug.

Earlier in 2022, Tempus had also partnered with GSK to advance oncology drug development, building on a previous collaboration with the pharma company to support clinical trial enrollment for a Phase II study of GSK's PARP inhibitor Zejula (niraparib). 

The firm also has ongoing partnerships with AstraZeneca focused on biomarker discovery and with Eli Lilly to increase access to genomic testing.

Click here to read the original news story.